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Background
Crohn's disease, a human disease similar to paratubercu-
losis in animals is the most painful and devastating dis-
ease that may involve infection with M. avium subsp.
paratuberculosis (MAP), different genetic polymorphisms
and an immune dysregulation syndrome [1-5]. Treatment
of Crohn's disease is most commonly based on 5-ami-
nosalicylic acid (5-ASA) compounds, corticosteroids, and
immunosuppressive agents. Recently, biological therapies
using monoclonal antibodies against inflammatory
cytokines have shown some positive results [6]. However,
all these therapies treat the symptoms not the cause of the
disease [6].
Antimycobacterial therapy against MAP has recently
showed promising results [7]. In fact, several authors pro-
vided convincing evidence that antimycobacterial com-
pounds may influence the course of the disease [4].
Currently, there are no antibiotics approved for the treat-
ment of Johne's disease or Crohn's disease. Considering
the worldwide magnitude and impact of health concerns
caused by MAP, we studied antimycobacterial activity of
different antituberculosis agents in vitro against MAP
bacilli of human and veterinary origins. Moreover, we
were interested to investigate the variability of susceptibil-
ity to antimycobacterial compounds of the MAP isolates
with respect to growth in agar medium and Congo red (a
planar hydrophobic molecule that binds to lipids and
lipoproteins, which are abundant in mycobacterial cell
walls) staining properties.
All the strains we used in this study were isolated from
humans and animals, the ATCC strain was a gift of Peter
Overduin, RIVM, Bilthoven, The Netherlands. Conven-
tional methods and a IS900 PCR test and sequencing of
the amplification products reconfirmed specific identity
of all the strains [1]. The strains (7 humans and 5 animals)
were tested against antimicrobial agents of several classes
(streptomycin, ciprofloxacin, ethambutol, dapsone,
rifampin, rifabutin and clarithromycin) which are com-
monly used for the treatment of mycobacterial diseases.
Bacteria were cultivated in Middlebrook7H9 medium
supplemented with Middlebrook ADC enrichment and
Mycobactin J following conventional methods [1,8].
MIGIT bottles were inoculated with 104 to 105 CFU/ml.
The antimycobacterial activity was determined by the
BACTEC MGIT 960 method with a modified protocol [8]
by adding mycobactin J and reading the mycobacterial
growth up to 90 days.
The concentration of the chemical agents tested were as
follows: streptomycin 0,5, 1, 2 and 4 μg/ml, ciprofloxacin
0,5, 1, 2, 4, 8 and 16 μg/ml, ethambutol 1, 2, 4, 8 and 16
μg/ml, rifampin 0.5, 1 and 2 μg/ml, rifabutin 0.5, 1, 2 μg/
ml, clarithromycin 2, 4, 8, 16 and 32 μg/ml and dapsone
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8, 16 and 32 μg/ml. Experiments were repeated three
times. The MICs were interpreted by measuring the
change in the daily GI (DGI) for the drug-containing vials
compared with the GI for the control vials,
Activities of the antibiotics tested in this work correlated
well with those described in previous reports on suscepti-
bility of mycobacteria to antimicrobial agents except for
clarythromicin [8,9]. Strains were prepared for the agar
assay and plated in triplicate on 7H10 agar medium con-
taining 100 μg/ml of Congo Red (Sigma Chemical Co. St.
Louis, Mo, USA). Plates were incubated for 40–60 days to
observe colony morphology: rough or smooth, opaque or
transparent, red or white [11].
We observed that streptomycin, rifabutin and rifampin,
revealed a characteristic low MIC of 0,5 to 4 μg/ml, also
ciprofloxacin shoed a low MIC (range 0,5–16) whereas,
dapsone's MIC was very high at 32 μg/ml. MICs of two
other drugs were 2–16 μg/ml and 2–32 μg/ml for etham-
butol and clarithtromycin respectively. Susceptibility data
on human and animal isolates were carefully compared
and summarized in Table 1. Briefly, for streptomycin the
MIC range was of 0,5-2 μg/ml in both animal and human
strains, for ciprofloxacin it was at 0.5–16 μg/ml, inde-
pendently of the source of isolation, while rifampin pro-
duced a MIC of 0.5–1 μg/ml in human and bovine strains
and of >2 μg/ml for 2 bovine and 1 animal isolate. Rifab-
utin MIC was very similar to rifampin. Also ethambutol
generated a MIC of 2–8 μg/ml in human strains and 4–16
μg/ml in animal strains. The highest MIC values were
observed for dapsone: 32 μg/ml for human strains but 16
μg/ml for animal isolates. Clarithromycin showed a MIC
ranging from 2 to 32 μg/ml independently of the isolation
source, which is in contrast with previous reports [9-11]
where they report a lower MIC of 0.5–4 μg/ml, probably
due to differences in the pH medium used. Our results
concerning growth in Congo red medium agar showed
prevalently a rough transparent colony morphotype with
white coloration, whereas no smooth opaque colonies
with red coloration on Congo Red agar were detected as
previously observed except that for ATCC 43015 [11],
moreover, no correlation with antimicrobial susceptibili-
ties was observed.
A number of antimicrobial agents have been used to com-
bat flare ups in Crohn's Disease. These have included Cip-
rofloxacin and metronidazole, used either alone or in
combination. In recent studies, Crohn's patients were
treated with 3 antibiotics for a minimum of 24 months
[4,7].
MAP multiplies much more slowly than M. tuberculosis,
and so its treatment length should probably be double if
not triple of that of the later. Other mycobacterial dis-
eases, such as leprosy, also require prolonged treatment.
Infection of the lung due to Mycobacterium avium complex
and other mycobacteria, in patients who are not immuno-
compromised, has been treated for about 15 months to
five years [12]. Moreover, considering that clarithromycin
and ciprofloxacin are widely used antibiotics, strains
resistant to these drugs can be very common. Up to now,
there is a urgent need of new information on the activity
of available antibiotic regimens against MAP.
In conclusion, these results might represent a good start-
ing point to consider different drugs for treatment of the
disease forms where involvement of MAP is suspected, in
particular Crohn's disease in humans.
Table 1: In vitro activity of several drugs against MAP strains
Drugs (μg/ml)
Strains STR CPX EMB DPS RIF RIB CLA
ATCC 43015 0.5 0.5 2 16 0.5 2 2
182 human 2 4 4 32 0.5 1 4
516 human 2 8 4 16 1 1 16
517 human 2 4 8 32 >2 >2 16
090 human 2 8 8 16 1 1 16
186 human 142 3 2 114
064 human 1 2 4 32 0.5 1 4
387 cow 2 2 4 16 0.5 0.5 2
436 cow 2 4 8 16 >2 >2 16
088 cow 11 6 1 6 1 6 > 2 > 2 3 2
033 cow 2 4 16 16 0.5 0,5 16
518 cow 28 1 6 1 6 122
STR: Streptomycin, CPX: Ciprofloxacin, EMB: Ethambutol, DPS: Dapsone, RIF: Rifampin, RIB: Rifabutin, CLA: Clarithromycin. Source of 
isolation of strains is also indicated. Numbers represent the MIC value for each drug.Publish with BioMed Central    and   every 
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